Nuevos retos en el tratamiento del cáncer urotelial.

5 / 38

Balar, Lancet 2017
123 patients
RR: 23% (CR 9%),
19 / 27 responses (70%) ongoing,
OS 15.9 m
9 (8%) patients discontinued for treatment-related adverse events
One treatment related death (sepsis)